Author:
Lepak A. J.,Reda A.,Marchillo K.,Van Hecker J.,Craig W. A.,Andes D.
Abstract
ABSTRACTCeftolozane is a novel cephalosporin with activity against drug-resistant pathogens, includingPseudomonas aeruginosaandStreptococcus pneumoniae. Thein vivoinvestigation reported here tested the limits of this drug against 20P. aeruginosaandS. pneumoniaeisolates across a wide MIC range and defined resistance mechanisms. The times above the MIC (T>MIC) targets for stasis and 1- and 2-log reductions were 31%, 39%, and 42% forP. aeruginosaand 18%, 24%, and 27% forS. pneumoniae, respectively. The 1-log endpoint was achieved for strains with MICs as high as 16 μg/ml.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference24 articles.
1. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America;Boucher;Clin. Infect. Dis.,2009
2. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010;Sievert;Infect. Control Hosp. Epidemiol.,2013
3. Estimating health care-associated infections and deaths in U.S. hospitals, 2002;Klevens;Public Health Rep.,2007
4. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes;Sader;Antimicrob. Agents Chemother.,2011
5. In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance;Bulik;Antimicrob. Agents Chemother.,2010
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献